EINPresswire/ -- The Positron-Emission Tomography (PET) market is driven by technological innovations, increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and ...
Dr. Mathieu Spriet is an Associate Professor of Diagnostic Imaging at the School of Veterinary Medicine at the University of California-Davis. In 2015, the Grayson-Jockey Club Research Foundation ...
It turns out that your annoying friend who insists on closing all of the window blinds and covering all of the glowing ...
Bright lights at night raise the risk of a heart attack or stroke, suggests a new study. Researchers found that exposure to ...
Positron Emission Tomography (PET) has become an indispensable tool in medical imaging, providing unique insights into the physiological processes of the ...
MedPage Today on MSN
Amyloid-Binding Radiotracer Spurs Hope for Better ATTR-CM Diagnosis
The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...
Higher levels of artificial light at night were linked to increased stress-related activity in the brain, inflamed arteries ...
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a ...
WISN 12 News on MSN
The number of daily steps you take may delay Alzheimer’s progression
Walking 3,000 to 7,500 steps daily may slow cognitive decline in older adults with early Alzheimer's, reducing tau buildup ...
Clinical Trials Arena on MSN
EMA approves Arctic Therapeutics’ trial of AT-001 for Alzheimer’s
The European Medicines Agency (EMA) has granted approval to Iceland-based Arctic Therapeutics to commence a Phase IIa trial ...
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNSLOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based ...
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果